These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
þ
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the quarterly period ended
February 28, 2013.
|
|
o
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the transition period from _________ to ________ .
|
| CALIFORNIA | 94-2424084 | |
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
|
400 KATO TERRACE
FREMONT, CA
|
94539 | |
| (Address of principal executive offices) | (Zip Code) |
| Large accelerated filer | o | Accelerated filer | o |
| Non-accelerated filer | o | Smaller reporting company | þ |
| (Do not check if a smaller reporting company) | |||
|
PART I.
|
FINANCIAL INFORMATION
|
||||
|
ITEM 1.
|
Condensed Consolidated Financial Statements (Unaudited)
|
3 | |||
|
Condensed Consolidated Balance Sheets as of
February 28, 2013 and May 31, 2012
|
3
|
||||
|
Condensed Consolidated Statements of Operations for the three
months and nine months ended February 28, 2013 and February 29, 2012
|
4 | ||||
|
Condensed Consolidated Statements of Comprehensive Income for
the three months and nine months ended February 28, 2013 and February 29, 2012
|
5 | ||||
|
Condensed Consolidated Statements of Cash Flows for the
nine months ended February 28, 2013 and February 29, 2012
|
6 | ||||
|
Notes to Condensed Consolidated Financial Statements
|
7 | ||||
|
ITEM 2.
|
Management's Discussion and Analysis of Financial Condition
and Results of Operations
|
16 | |||
|
ITEM 3.
|
Quantitative and Qualitative Disclosures about Market Risks
|
21 | |||
|
ITEM 4.
|
Controls and Procedures
|
22 | |||
|
PART II.
|
OTHER INFORMATION
|
||||
|
ITEM 1.
|
Legal Proceedings
|
22 | |||
|
ITEM 1A.
|
Risk Factors
|
22 | |||
|
ITEM 2.
|
Unregistered Sales of Equity Securities and Use of Proceeds
|
30 | |||
|
ITEM 3.
|
Defaults Upon Senior Securities
|
30 | |||
|
ITEM 4.
|
Mine Safety Disclosures
|
30 | |||
|
ITEM 5.
|
Other Information
|
30 | |||
|
ITEM 6.
|
Exhibits
|
30 | |||
| SIGNATURE PAGE | 31 | ||||
| Index to Exhibits | 32 | ||||
|
February 28,
|
May 31,
|
|||||||
|
2013
|
2012
|
|||||||
| (1) | ||||||||
|
ASSETS
|
||||||||
|
Current assets:
|
||||||||
|
Cash and cash equivalents
|
$ | 1,381 | $ | 2,073 | ||||
|
Accounts receivable, net of allowances for
doubtful accounts of $24 and
$39 at
February 28, 2013 and May 31, 2012, respectively
|
1,570 | 2,588 | ||||||
|
Inventories
|
5,722 | 6,070 | ||||||
|
Prepaid expenses and other
|
205 | 197 | ||||||
|
Total current assets
|
8,878 | 10,928 | ||||||
|
Property and equipment, net
|
378 | 510 | ||||||
|
Other assets
|
159 | 175 | ||||||
|
Total assets
|
$ | 9,415 | $ | 11,613 | ||||
|
LIABILITIES AND SHAREHOLDERS' EQUITY
|
||||||||
|
Current liabilities:
|
||||||||
|
Line of credit
|
$ | 1,215 | $ | 1,408 | ||||
|
Accounts payable
|
1,517 | 1,507 | ||||||
|
Accrued expenses
|
1,554 | 1,385 | ||||||
|
Deferred revenue, short-term
|
238 | 555 | ||||||
|
Total current liabilities
|
4,524 | 4,855 | ||||||
|
Income tax payable
|
115 | 125 | ||||||
|
Deferred lease commitment
|
122 | 179 | ||||||
|
Deferred revenue, long-term
|
122 | -- | ||||||
|
Total liabilities
|
4,883 | 5,159 | ||||||
|
Aehr Test Systems shareholders' equity:
|
||||||||
|
Common stock, $0.01 par value:
|
||||||||
|
Issued and outstanding: 9,363 shares and
9,135 shares at February 28, 2013 and
May 31, 2012, respectively
|
94 | 91 | ||||||
|
Additional paid-in capital
|
49,251 | 48,622 | ||||||
|
Accumulated other comprehensive income
|
2,469 | 2,458 | ||||||
|
Accumulated deficit
|
(47,261 | ) | (44,695 | ) | ||||
|
Total Aehr Test Systems shareholders' equity
|
4,553 | 6,476 | ||||||
|
Noncontrolling interest
|
(21 | ) | (22 | ) | ||||
|
Total shareholders' equity
|
4,532 | 6,454 | ||||||
|
Total liabilities and shareholders' equity
|
$ | 9,415 | $ | 11,613 | ||||
|
Three Months Ended
|
Nine Months Ended
|
|||||||||||||||
|
February 28,
|
February 29,
|
February 28,
|
February 29,
|
|||||||||||||
|
2013
|
2012
|
2013
|
2012
|
|||||||||||||
|
Net sales
|
$ | 3,340 | $ | 2,855 | $ | 13,226 | $ | 10,845 | ||||||||
|
Cost of sales
|
2,575 | 1,747 | 7,742 | 6,807 | ||||||||||||
|
Gross profit
|
765 | 1,108 | 5,484 | 4,038 | ||||||||||||
|
Operating expenses:
|
||||||||||||||||
|
Selling, general and administrative
|
1,511 | 1,525 | 5,368 | 4,654 | ||||||||||||
|
Research and development
|
685 | 933 | 2,577 | 3,054 | ||||||||||||
|
Total operating expenses
|
2,196 | 2,458 | 7,945 | 7,708 | ||||||||||||
|
Loss from operations
|
(1,431 | ) | (1,350 | ) | (2,461 | ) | (3,670 | ) | ||||||||
|
Interest expense
|
(18 | ) | -- | (43 | ) | -- | ||||||||||
|
Gain on sale of long-term investment
|
-- | -- | -- | 990 | ||||||||||||
|
Other (expense) income, net
|
(9 | ) | 7 | (43 | ) | 53 | ||||||||||
|
Loss before income tax (expense) benefit
|
(1,458 | ) | (1,343 | ) | (2,547 | ) | (2,627 | ) | ||||||||
|
Income tax (expense) benefit
|
-- | (18 | ) | (18 | ) | 17 | ||||||||||
|
Net loss
|
(1,458 | ) | (1,361 | ) | (2,565 | ) | (2,610 | ) | ||||||||
|
Less: Net income attributable to the noncontrolling interest
|
-- | -- | -- | 1 | ||||||||||||
|
Net loss attributable to Aehr Test Systems common shareholders
|
$ | (1,458 | ) | $ | (1,361 | ) | $ | (2,565 | ) | $ | (2,611 | ) | ||||
|
Net loss per share – basic
|
$ | (0.16 | ) | $ | (0.15 | ) | $ | (0.28 | ) | $ | (0.29 | ) | ||||
|
Net loss per share – diluted
|
$ | (0.16 | ) | $ | (0.15 | ) | $ | (0.28 | ) | $ | (0.29 | ) | ||||
|
Shares used in per share calculations:
|
||||||||||||||||
|
Basic
|
9,363 | 9,055 | 9,276 | 8,989 | ||||||||||||
|
Diluted
|
9,363 | 9,055 | 9,276 | 8,989 | ||||||||||||
|
Three Months Ended
|
Nine Months Ended
|
|||||||||||||||
|
February 28,
|
February 29,
|
February 28,
|
February 29,
|
|||||||||||||
|
2013
|
2012
|
2013
|
2012
|
|||||||||||||
|
Net loss
|
$ | (1,458 | ) | $ | (1,361 | ) | $ | (2,565 | ) | $ | (2,610 | ) | ||||
| Other comprehensive (loss) income, net of tax: | ||||||||||||||||
|
Foreign currency translation gain (loss)
|
(13 | ) | (24 | ) | 11 | (74 | ) | |||||||||
|
Total comprehensive loss
|
(1,471 | ) | (1,385 | ) | (2,554 | ) | (2,684 | ) | ||||||||
|
Less: Comprehensive income attributable to noncontrolling interest
|
-- | -- | -- | 1 | ||||||||||||
|
Comprehensive loss, attributable to Aehr Test Systems
|
$ | (1,471 | ) | $ | (1,385 | ) | $ | (2,554 | ) | $ | (2,685 | ) | ||||
|
Nine Months Ended
|
||||||||
|
February 28,
|
February 29,
|
|||||||
|
2013
|
2012
|
|||||||
|
Cash flows from operating activities:
|
||||||||
|
Net loss
|
$ | (2,565 | ) | $ | (2,610 | ) | ||
|
Adjustments to reconcile net loss to
net cash used in operating activities:
|
||||||||
|
Stock-based compensation expense
|
427 | 519 | ||||||
|
Provision for doubtful accounts
|
(15 | ) | (9 | ) | ||||
|
Gain on sale of long-term investment
|
-- | (990 | ) | |||||
|
Depreciation and amortization
|
247 | 388 | ||||||
|
Changes in operating assets and liabilities:
|
||||||||
|
Accounts receivable
|
951 | 535 | ||||||
|
Inventories
|
375 | (694 | ) | |||||
|
Prepaid expenses and other
|
(11 | ) | (90 | ) | ||||
|
Accounts payable
|
379 | 106 | ||||||
|
Accrued expenses and deferred revenue
|
(49 | ) | (274 | ) | ||||
|
Income tax payable
|
15 | (44 | ) | |||||
|
Deferred lease commitment
|
(57 | ) | (43 | ) | ||||
|
Net cash used in
operating activities
|
(303 | ) | (3,206 | ) | ||||
|
Cash flows from investing activities:
|
||||||||
|
Proceeds from sale of investments
|
-- | 1,375 | ||||||
|
Purchase of property and equipment
|
(126 | ) | (20 | ) | ||||
|
Net cash (used in) provided by
investing activities
|
(126 | ) | 1,355 | |||||
|
Cash flows from financing activities:
|
||||||||
|
Line of credit (repayments) borrowings, net
|
(193 | ) | 716 | |||||
|
Proceeds from issuance of common stock
and exercise of stock options
|
180 | 114 | ||||||
|
Net cash (used in) provided by
financing activities
|
(13 | ) | 830 | |||||
|
Effect of exchange rates on cash
|
(250 | ) | (24 | ) | ||||
|
Net decrease in cash and
cash equivalents
|
(692 | ) | (1,045 | ) | ||||
|
Cash and cash equivalents, beginning of period
|
2,073 | 4,020 | ||||||
|
Cash and cash equivalents, end of period
|
$ | 1,381 | $ | 2,975 | ||||
| Supplemental disclosure of non-cash flow information: | ||||||||
| Net change in capitalized share-based compensation | $ | 25 | -- | |||||
|
1.
|
BASIS OF PRESENTATION
|
|
2.
|
STOCK-BASED COMPENSATION
|
|
Three Months Ended
|
Nine Months Ended
|
|||||||||||||||
|
February 28,
|
February 29,
|
February 28,
|
February 29,
|
|||||||||||||
|
2013
|
2012
|
2013
|
2012
|
|||||||||||||
|
Stock-based compensation in the form of employee stock options and ESPP shares, included in:
|
||||||||||||||||
|
Cost of sales
|
$ | 9 | $ | 25 | $ | 26 | $ | 71 | ||||||||
|
Selling, general and administrative
|
159 | 111 | 315 | 299 | ||||||||||||
|
Research and development
|
33 | 46 | 86 | 149 | ||||||||||||
|
Total stock-based compensation
|
$ | 201 | $ | 182 | $ | 427 | $ | 519 | ||||||||
|
Three Months Ended
|
Nine Months Ended
|
|||||||||||||||
|
February 28,
|
February 29,
|
February 28,
|
February 29, | |||||||||||||
|
2013
|
2012
|
2013
|
2012 | |||||||||||||
|
Option Plan Shares
|
||||||||||||||||
|
Expected Term (in years)
|
5 | 5 | 5 | 5 | ||||||||||||
|
Volatility
|
0.94 | 0.85 | 0.91 | 0.83 | ||||||||||||
|
Expected Dividend
|
$ | 0.00 | $ | 0.00 | $ | 0.00 | $ | 0.00 | ||||||||
|
Risk-free Interest Rates
|
0.76 | % | 0.84 | % | 0.72 | % | 1.14 | % | ||||||||
|
Estimated Forfeiture Rate
|
0.25 | % | 0.25 | % | 0.25 | % | 0.25 | % | ||||||||
|
Weighted Average Grant Date Fair Value
|
$ | 0.62 | $ | 0.43 | $ | 0.78 | $ | 0.59 | ||||||||
|
Nine Months Ended
February 29,
2012
|
||||
|
Employee Stock Purchase Plan Purchase Rights
|
||||
|
Expected Term (in years)
|
0.5-2.0 | |||
|
Volatility
|
0.79-0.98 | |||
|
Expected Dividend
|
$ | 0.00 | ||
|
Risk-free Interest Rates
|
0.1%-1.1% | |||
|
Estimated Forfeiture Rate
|
0% | |||
|
Weighted Average Grant Date Fair Value
|
$ | 0.40 | ||
| Outstanding Options | ||||||||||||||||
|
Weighted
|
||||||||||||||||
|
Number
|
Average
|
Aggregate
|
||||||||||||||
|
Available
|
of
|
Exercise
|
Intrinsic
|
|||||||||||||
|
Shares
|
Shares
|
Price
|
Value
|
|||||||||||||
|
Balances, May 31, 2012
|
839 | 2,957 | $ | 2.40 | $ | 587 | ||||||||||
|
Options granted
|
(439 | ) | 439 | $ | 1.28 | |||||||||||
|
Options terminated
|
402 | (402 | ) | $ | 4.48 | |||||||||||
|
Plan shares expired
|
(180 | ) | -- | |||||||||||||
|
Options exercised
|
-- | (101 | ) | $ | 0.67 | |||||||||||
|
Balances, August 31, 2012
|
622 | 2,893 | $ | 2.00 | $ | 340 | ||||||||||
|
Additional shares reserved
|
1,185 | -- | ||||||||||||||
|
Options granted
|
(180 | ) | 180 | $ | 0.81 | |||||||||||
|
Options terminated
|
91 | (91 | ) | $ | 3.92 | |||||||||||
|
Balances, November 30, 2012
|
1,718 | 2,982 | $ | 1.87 | $ | 167 | ||||||||||
|
Options granted
|
(50 | ) | 50 | $ | 0.97 | |||||||||||
|
Options terminated
|
65 | (65 | ) | $ | 4.33 | |||||||||||
|
Plan shares expired
|
(4 | ) | -- | |||||||||||||
|
Balances, February 28, 2013
|
1,729 | 2,967 | $ | 1.80 | $ | 166 | ||||||||||
|
Options fully vested and expected to
vest at February 28, 2013
|
2,908 | $ | 1.80 | $ | 162 | |||||||||||
|
Options exercisable at February 28, 2013
|
1,750 | $ | 2.26 | $ | 66 | |||||||||||
|
Options Outstanding
at February 28, 2013
|
Options Excercisable
at
February 28, 2013
|
|||||||||||||||||||||||||||||
|
Range of
Exercise
Prices
|
Number
Outstanding
Shares
|
Weighted
Average Remaining Contractual Life (Years) |
Weighted Average Exercise Price
|
Number
Exercisable
Shares
|
Weighted
Average Remaining Contractual Life (Years) |
Weighted Average Exercise Price |
Aggregate
Intrinsic
Value
|
|||||||||||||||||||||||
| $0.59-$0.97 | 1,167 | 4.45 | $ | 0.76 | 750 | 3.51 | $ | 0.81 | ||||||||||||||||||||||
| $1.10-$2.52 | 1,587 | 4.06 | $ | 1.56 | 787 | 2.90 | $ | 1.76 | ||||||||||||||||||||||
| $6.00-$9.30 | 108 | 0.37 | $ | 8.53 | 108 | 0.37 | $ | 8.53 | ||||||||||||||||||||||
| $9.94-$9.94 | 105 | 0.32 | $ | 9.94 | 105 | 0.32 | $ | 9.94 | ||||||||||||||||||||||
| $0.59-$9.94 | 2,967 | 3.95 | $ | 1.80 | 1,750 | 2.85 | $ | 2.26 | $ | 66 | ||||||||||||||||||||
|
3.
|
EARNINGS PER SHARE
|
|
Three Months Ended
|
Nine Months Ended
|
|||||||||||||||
|
February 28,
|
February 29,
|
February 28,
|
February 29,
|
|||||||||||||
|
2013
|
2012
|
2013
|
2012
|
|||||||||||||
|
(in thousands, except per share amounts)
|
||||||||||||||||
|
Numerator: Net loss
|
$ | (1,458 | ) | $ | (1,361 | ) | $ | (2,565 | ) | $ | (2,611 | ) | ||||
|
Denominator for basic net loss
per share:
|
||||||||||||||||
|
Weighted-average shares outstanding
|
9,363 | 9,055 | 9,276 | 8,989 | ||||||||||||
|
Shares used in basic net loss
per share calculation
|
9,363 | 9,055 | 9,276 | 8,989 | ||||||||||||
|
Effect of dilutive securities
|
-- | -- | -- | -- | ||||||||||||
|
Denominator for diluted net loss
per share
|
9,363 | 9,055 | 9,276 | 8,989 | ||||||||||||
|
Basic net loss per share
|
$ | (0.16 | ) | $ | (0.15 | ) | $ | (0.28 | ) | $ | (0.29 | ) | ||||
|
Diluted net loss per share
|
$ | (0.16 | ) | $ | (0.15 | ) | $ | (0.28 | ) | $ | (0.29 | ) | ||||
|
4.
|
FAIR VALUE OF FINANCIAL INSTRUMENTS
|
|
Balance as of
|
||||||||||||||||
|
February 28, 2013
|
Level 1
|
Level 2
|
Level 3
|
|||||||||||||
|
Money market funds
|
$ | 102 | $ | 102 | $ | -- | $ | -- | ||||||||
|
Assets
|
$ | 102 | $ | 102 | $ | -- | $ | -- | ||||||||
|
Liabilities
|
$ | -- | $ | -- | $ | -- | $ | -- | ||||||||
|
Balance as of
|
||||||||||||||||
|
May 31, 2012
|
Level 1
|
Level 2
|
Level 3
|
|||||||||||||
|
Money market funds
|
$ | 2 | $ | 2 | $ | -- | $ | -- | ||||||||
|
Assets
|
$ | 2 | $ | 2 | $ | -- | $ | -- | ||||||||
|
Liabilities
|
$ | -- | $ | -- | $ | -- | $ | -- | ||||||||
|
5.
|
ACCOUNTS RECEIVABLE, NET
|
|
6.
|
INVENTORIES
|
|
February 28,
2013
|
May 31,
2012
|
|||||||
|
Raw materials and sub-assemblies
|
$ | 2,843 | $ | 3,218 | ||||
|
Work in process
|
2,879 | 2,657 | ||||||
|
Finished goods
|
-- | 195 | ||||||
| $ | 5,722 | $ | 6,070 | |||||
|
7.
|
SEGMENT INFORMATION
|
|
(in thousands)
|
United
States
|
Asia
|
Europe
|
Total
|
||||||||||||
|
Three months ended
February 28, 2013
:
|
||||||||||||||||
|
Net sales
|
$ | 2,100 | $ | 1,188 | $ | 52 | $ | 3,340 | ||||||||
|
Property and equipment, net
|
321 | 57 | -- | 378 | ||||||||||||
|
Nine months ended
February 28, 2013
:
|
||||||||||||||||
|
Net sales
|
$ | 6,095 | $ | 6,546 | $ | 585 | $ | 13,226 | ||||||||
|
Property and equipment, net
|
321 | 57 | -- | 378 | ||||||||||||
|
Three months ended
February 29, 2012
:
|
||||||||||||||||
|
Net sales
|
$ | 2,184 | $ | 151 | $ | 520 | $ | 2,855 | ||||||||
|
Property and equipment, net
|
517 | 66 | 4 | 587 | ||||||||||||
|
Nine months ended
February 29, 2012
:
|
||||||||||||||||
|
Net sales
|
$ | 7,076 | $ | 2,338 | $ | 1,431 | $ | 10,845 | ||||||||
|
Property and equipment, net
|
517 | 66 | 4 | 587 | ||||||||||||
|
8.
|
PRODUCT WARRANTIES
|
|
Three Months Ended
|
Nine Months Ended
|
|||||||||||||||
|
February 28,
|
February 29,
|
February 28,
|
February 29,
|
|||||||||||||
|
2013
|
2012
|
2013
|
2012
|
|||||||||||||
|
Balance at the beginning of the period
|
$ | 174 | $ | 129 | $ | 91 | $ | 103 | ||||||||
|
Accruals for warranties issued
during the period
|
162 | 35 | 412 | 176 | ||||||||||||
|
Settlement made during the period
(in cash or in kind)
|
(139 | ) | (52 | ) | (306 | ) | (167 | ) | ||||||||
|
Balance at the end of the period
|
$ | 197 | $ | 112 | $ | 197 | $ | 112 | ||||||||
|
9.
|
INCOME TAXES
|
|
10.
|
LINE OF CREDIT
|
|
11.
|
RECENT ACCOUNTING PRONOUNCEMENTS
|
|
12.
|
SUBSEQUENT EVENTS
|
|
Three Months Ended
|
Nine Months Ended
|
|||||||||||||||
|
February 28,
|
February 29,
|
February 28,
|
February 29,
|
|||||||||||||
|
2013
|
2012
|
2013
|
2012
|
|||||||||||||
|
Net sales
|
100.0 | % | 100.0 | % | 100.0 | % | 100.0 | % | ||||||||
|
Cost of sales
|
77.1 | 61.2 | 58.5 | 62.8 | ||||||||||||
|
Gross profit
|
22.9 | 38.8 | 41.5 | 37.2 | ||||||||||||
|
Operating expenses:
|
||||||||||||||||
|
Selling, general and administrative
|
45.2 | 53.4 | 40.6 | 42.9 | ||||||||||||
|
Research and development
|
20.5 | 32.7 | 19.5 | 28.2 | ||||||||||||
|
Total operating expenses
|
65.7 | 86.1 | 60.1 | 71.1 | ||||||||||||
|
Loss from operations
|
(42.8 | ) | (47.3 | ) | (18.6 | ) | (33.9 | ) | ||||||||
|
Interest expense
|
(0.6 | ) | -- | (0.4 | ) | -- | ||||||||||
|
Gain on sale of long-term investment
|
-- | -- | -- | 9.1 | ||||||||||||
|
Other (expense) income, net
|
(0.3 | ) | 0.2 | (0.3 | ) | 0.5 | ||||||||||
|
Loss before income tax
(expense) benefit
|
(43.7 | ) | (47.1 | ) | (19.3 | ) | (24.3 | ) | ||||||||
|
Income tax (expense) benefit
|
-- | (0.6 | ) | (0.1 | ) | 0.2 | ||||||||||
|
Net loss
|
(43.7 | )% | (47.7 | )% | (19.4 | )% | (24.1 | )% | ||||||||
| Aehr Test Systems | |||
| (Registrant) | |||
|
Date: April 12, 2013
|
By:
|
/s/ GAYN ERICKSON | |
| Gayn Erickson | |||
| President and Chief Executive Officer | |||
|
Date: April 12, 2013
|
By:
|
/s/ GARY L. LARSON | |
| Gary L. Larson | |||
| Vice President of Finance and | |||
| Chief Financial Officer |
|
Exhibit No.
|
Description
|
|
|
3.1(1)
|
Restated Articles of Incorporation of the Company.
|
|
|
3.2(2)
|
Amended and Restated Bylaws of the Company.
|
|
|
10.31(3)
|
Offer Letter dated March 5, 2013, between the Company and Rhea J.
Posedel
|
|
|
10.32(4)
|
Amended and Restated Change of Control Severance Agreement dated
March 5, 2013, between the Company and Rhea J. Posedel.
|
|
|
10.33(5)
|
Common Stock Purchase Agreement by and among the Company and the
Investors (defined therein), dated as of March 15, 2013.
|
|
|
31.1
|
Certification of Chief Executive Officer pursuant to Rules
13a-14(a) and 15d-14(a) promulgated under the Securities
Exchange Act of 1934, as amended, as adopted pursuant to
Section 302(a) of the Sarbanes-Oxley Act of 2002.
|
|
|
31.2
|
Certification of Chief Financial Officer pursuant to Rules
13a-14(a) and 15d-14(a) promulgated under the Securities
Exchange Act of 1934, as amended, as adopted pursuant to
Section 302(a) of the Sarbanes-Oxley Act of 2002.
|
|
|
32
|
Certification of Chief Executive Officer and Chief Financial
Officer pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*
|
|
|
101.INS
|
XBRL Instance Document**
|
|
|
101.SCH
|
XBRL Taxonomy Extension Schema Document**
|
|
|
101.CAL
|
XBRL Taxonomy Extension Calculation Linkbase Document**
|
|
|
101.DEF
|
XBRL Taxonomy Extension Definition Linkbase Document**
|
|
|
101.LAB
|
XBRL Taxonomy Extension Label Linkbase Document**
|
|
|
101.PRE
|
XBRL Taxonomy Extension Presentation Linkbase Document**
|
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|